CLINICAL TRIAL: ANTITHYMOCYTE GLOBULIN ON PRESERVING BETA CELL FUNCTION IN NEW O

临床试验：抗胸腺细胞球蛋白在新 O 中保留 β 细胞功能

• 批准号: 7982166
• 负责人: FRANCINE R. KAUFMAN
• 金额: $ 1.97万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982166
• 关键词: Antibodies; Antithymoglobulin; Back; Beta Cell; Binding; Cell physiology; Cell surface; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Leukocytes; Oryctolagus cuniculus; Pharmaceutical Preparations; Proteins; Research; Research Personnel; Resources; Source; Surface; T-Lymphocyte; Testing; United States National Institutes of Health; design; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The experimental drug Thymoglobulin (Genzyme Corporation), a rabbit antithymocyte globulin (ATG), will be tested in this research study. Thymoglobulin is an antibody medication. Antibodies are specialized proteins designed to block or bind to target proteins on the cell surface. In the case of Thymoglobulin it binds to proteins on the surface of your white blood cells (mainly T cells) and either removes them from your body or alters their function. The researchers are hoping that the remaining T cells or the new T cells that grow back will not attack the beta cells.

这个子项目是众多研究子项目之一